

Ref No.: ZLL/CS/BSE/NSE

Date: 21.07.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of Marketing Authorization for Rizatriptan Benzoate Orally Disintegrating Strips in Australia

Please find enclosed herewith the Press Release relating to grant of Marketing Authorization for “Rizatriptan Benzoate Orally Disintegrating Strips” in Australia by the Therapeutic Goods Administration (TGA), to ZIMTAS PTY LTD. (“ZIMTAS”), Subsidiary of the company.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: as above

ZIM LABORATORIES LIMITED

PRESS RELEASE

ZIM Laboratories Receives First Marketing Authorization in Australia for Rizatriptan Benzoate Orally Disintegrating Films via ZIMTAS

Nagpur, India – July 21, 2025

ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company is pleased to announce that the Therapeutic Goods Administration (TGA), Australia has granted Marketing Authorization (MA) for its Central Nervous System (CNS) product “Rizatriptan Benzoate Orally Disintegrating Films” through its Australian Subsidiary, ZIMTAS.

This approval marks ZIM’s first Marketing Authorization in Australia and represents an important milestone in the Company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies.

Rizatriptan, a selective 5-HT_{1B/1D} receptor agonist, is indicated for the acute treatment of migraine attacks, with or without aura, in adults. The orally disintegrating film (ODF) formulation developed using ZIM’s proprietary technology platform offers a patient-friendly alternative that enables rapid onset of action without the need for water, making it especially convenient for patients experiencing nausea or vomiting during migraine episodes.

This authorization is expected to:

- Facilitate commercial launch in the Australian market via ZIMTAS.
- Serve as a springboard for additional regulatory filings across the Asia-Pacific region.
- Further validate ZIM’s oral thin film platform as a globally relevant drug delivery technology.

This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience.